APOE and neurodegenerative disease: In humans, prior studies have shown that while APOE4 carriers are at elevated baseline risk for cardiovascular and neurodegenerative disease, they often experience disproportionately greater improvements in aerobic fitness, vascular function, or cardiometabolic risk markers following structured exercise compared with non-carriers, particularly under adverse metabolic conditions [7,13,14].